CoChat

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background: Results of our previous study showed high objective response but short-term activity of apatinib in advanced osteosarcoma. We aimed to investigate the activity of apatinib in combination with camrelizumab in patients with inoperable high-grade osteosarcoma progressing after chemotherapy. Methods: This open-label, phase 2 trial was conducted at Peking University People’s Hospital. We enrolled patients with advanced osteosarcoma progressed after chemotherapy. Patients received 500 mg apatinib orally once daily plus 200 mg camrelizumab by intravenous infusion every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) and clinical benefit rate at 6 months, which were based on RECIST V.1.1. Results: 43 patients were enrolled between January 25 and September 4, 2018. With median follow-up time of 48.3 (Q1, Q3, 30.6, 66.6) weeks, 13 (30.23%, 95% CI 17.2%, 40.1%) of 43 patients were progression free at 6 months and the 6-month PFS rate was 50.9% (95% CI 34.6%, 65.0%). Until final follow-up, the objective response rate was 20.9% (9/43) and two patients with durable disease control were observed. Patients with programmed cell death 1 ligand-1 (PD-L1) tumor proportion score ≥5% and pulmonary metastases tended to have a longer PFS in comparison to the others (p=0.004 and 0.017, respectively). Toxic effects led to dose reductions, or interruptions, or both in 24 (55.8%) of 43 patients and permanent discontinuation in 4 (9.3%) patients. There were no treatment-related deaths. Conclusions: Although the combination of apatinib and camrelizumab seemed to prolong PFS in comparison to single agent apatinib in treating advanced osteosarcoma, it did not reach the prespecified target of 6-month PFS of 60% or greater. Overexpression of PD-L1 and the presence of pulmonary metastases only were associated with longer PFS. Trial registration number: NCT03359018.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000798

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile. OS, verall survival; PFS, progression-free survival.
Figure 1 Trial profile. OS, verall survival; PFS, progression-free survival.CC BY-NC · PubMed Central
Figure 2 Kaplan-Meier plots for progression-free survival (PFS) in 43 patients (intention-to-treat population).
Figure 2 Kaplan-Meier plots for progression-free survival (PFS) in 43 patients (intention-to-treat population).CC BY-NC · PubMed Central
Figure 3 Kaplan-Meier plots for overall survival (OS) in 43 patients (intention-to-treat population).
Figure 3 Kaplan-Meier plots for overall survival (OS) in 43 patients (intention-to-treat population).CC BY-NC · PubMed Central
Figure 4 Kaplan-Meier plot for progression-free survival (PFS) based on programmed cell death 1 ligand-1 (PD-L1) immunohistochemical expression. Anti-PD-L1 antibodies: clone 22C3; Cat#M3653; DAKO. Log-rank test p=0.004. Crosses indicate censoring.
Figure 4 Kaplan-Meier plot for progression-free survival (PFS) based on programmed cell death 1 ligand-1 (PD-L1) immunohistochemical expression. Anti-PD-L1 antibodies: clone 22C3; Cat#M3653; DAKO. Log-rank test p=0.004. Crosses indicate censoring.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 145

Metadata

Authors
Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., Yan, T., Yang, R., Sun, K., Shen, D., & Li, Y.
Affiliations
  • Peking University People's Hospital (CN)
  • Peking University Shougang Hospital (CN)
Corresponding author
Guo, Wei
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-05
Volume
8
Issue
1
Pages
e000798
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3021046581
Cited by
145
References
29
Citations by year
2026: 14 · 2025: 23 · 2024: 25 · 2023: 28 · 2022: 32 · 2021: 21 · 2020: 2
FWCI
11.70
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81572633)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
apatinib, camrelizumab, anti-PD-1 therapy, PD-L1 expression, lung metastasis, progression-free survival, combination therapy, chemotherapy-refractory disease, predictive biomarkers, treatment toxicity, VEGFR-2 inhibition, immune checkpoint inhibitors, clinical benefit rate, objective response rate, prognostic factors, durable disease control
MeSH terms
Progression-Free Survival, Immune Checkpoint Inhibitors, Administration, Oral, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Pyridines, Osteosarcoma, Disease Progression, Protein Kinase Inhibitors, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1136/jitc-2020-000798
The paper
Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., Yan, T., Yang, R., Sun, K., Shen, D., & Li, Y. (2020). Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.